Jubilee's steroid vs natural bodybuilder debate, fact-checked
Quick answer
The debate touches on medically legitimate uses of anabolic steroids for hypogonadism and wasting diseases, but the claim that most men over 30 have testosterone at female levels is inconsistent with population data showing median values near 600 ng/dL in that age group. Confirmed hypogonadism requires both symptomatic presentation and lab values below 300 ng/dL, affecting a small minority of adult men, not a majority. TRT prescribed for confirmed deficiency is clinically distinct from supraphysiological dosing for aesthetic or performance purposes.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @jubilee actually say?
The video is a roundtable debate between self-identified natural bodybuilders and apparent steroid users. The most medically specific claim made is that "most men over the age of 30 have female level testosterone." A speaker also argues that steroids are being unfairly vilified because they serve legitimate therapeutic purposes, citing AIDS patients and prednisone as examples. Another participant pushes back, arguing most gym-goers use performance-enhancing drugs for aesthetics, not medicine. The conversation is chaotic but the core medical assertion, that low testosterone is more dangerous than normalized levels via TRT, is the one worth examining closely.
Does the science back this up?
Partially, but the framing is sloppy enough to mislead. The claim that "most men over 30 have female-level testosterone" is flatly wrong. According to reference ranges published by the Endocrine Society, the normal male range is roughly 300 to 1000 ng/dL. Women's ranges run approximately 15 to 70 ng/dL. The median testosterone in men aged 30 to 40 sits around 600 ng/dL (Bhasin et al., 2010, Journal of Clinical Endocrinology and Metabolism). Hypogonadism, defined as levels below 300 ng/dL with clinical symptoms, affects an estimated 2 to 6 percent of adult men, not a majority.
The separate claim that low testosterone carries real health risks is better supported. Studies have associated hypogonadism with increased cardiovascular risk, metabolic syndrome, depression, and bone density loss (Khera et al., 2016, Journal of Urology). So the direction of the argument is not wrong. The numbers used to get there are.
What did they get wrong (or right)?
Wrong: "Most men over the age of 30 have female level testosterone." This is not supported by population data. It conflates the general male population with a subset experiencing clinically significant decline. Spreading this statistic, even in a debate format, pushes people toward unnecessary medical anxiety and potentially unnecessary interventions.
Right: The therapeutic use argument holds up. Anabolic steroids are FDA-approved for hypogonadism, delayed puberty, and muscle wasting in diseases including HIV/AIDS (Bhasin et al., 1996, New England Journal of Medicine). Prednisone is a corticosteroid, not an anabolic steroid, so that comparison is scientifically imprecise, but the broader point that "steroids" as a category includes medically legitimate compounds is accurate.
Also right: The acknowledgment that there is a physical ceiling natural athletes cannot surpass is consistent with exercise science literature. Studies comparing muscle hypertrophy in natural versus enhanced athletes consistently show divergent outcomes at elite levels (Kadi et al., 1999, Histochemistry and Cell Biology).
What should you actually know?
If you are watching this video and walking away thinking your testosterone is probably in female ranges, stop. Get a blood panel. A single morning total testosterone test, ideally repeated once, is the starting point for any legitimate hypogonadism diagnosis. Symptoms matter too. Fatigue, low libido, and mood changes need to correlate with lab values before TRT is even a conversation worth having with a physician.
TRT is not the same as running a bodybuilding cycle. Therapeutic dosing aims to restore levels to the normal physiological range, typically 400 to 700 ng/dL. Supraphysiological dosing, the kind associated with aesthetic or performance goals, carries documented risks including erythrocytosis, cardiovascular strain, testicular atrophy, and suppression of natural hormone production (Morgentaler et al., 2015, Mayo Clinic Proceedings).
- TRT under physician supervision, for confirmed hypogonadism, is a legitimate medical treatment.
- Self-administering testosterone without a diagnosis is a different category of decision entirely, with different risk profiles.
- Anyone considering TRT should work with an endocrinologist or urologist, not a social media debate for framing.
What is the bottom line for FormBlends users?
This video gets credit for trying to separate therapeutic steroid use from recreational abuse. That distinction matters and not enough fitness content makes it. But the testosterone statistics thrown around are wrong, and wrong statistics drive bad decisions. If a video with 1.2 million views tells you your hormones are probably at female levels, and you are a healthy man in your 30s, the evidence says that is almost certainly not true. Get tested before you treat anything.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 11 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Jubilee's steroid vs natural bodybuilder debate, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
Jubilee's steroid vs natural bodybuilder debate, fact-checked should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
Compare available products and select the relevant treatment page for its specific next step.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
The debate touches on medically legitimate uses of anabolic steroids for hypogonadism and wasting diseases, but the claim that most men over 30 have testosterone at female levels is inconsistent with population data showing median values near 600 ng/dL in that age group.
FormBlends verdict
The debate touches on medically legitimate uses of anabolic steroids for hypogonadism and wasting diseases, but the claim that most men over 30 have testosterone at female levels is inconsistent with population data showing median values near 600 ng/dL in that age group. Confirmed hypogonadism requires both symptomatic presentation and lab values below 300 ng/dL, affecting a small minority of adult men, not a majority. TRT prescribed for confirmed deficiency is clinically distinct from supraphysiological dosing for aesthetic or performance purposes.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The debate touches on medically legitimate uses of anabolic steroids for hypogonadism and wasting diseases, but the claim that most men over 30 have testosterone at female levels is inconsistent with population data showing median values near 600 ng/dL in that age group. Confirmed hypogonadism requires both symptomatic presentation and lab values below 300 ng/dL, affecting a small minority of adult men, not a majority. TRT prescribed for confirmed deficiency is clinically distinct from supraphysiological dosing for aesthetic or performance purposes.
- Median testosterone in men aged 30 to 40 is approximately 600 ng/dL, not comparable to female reference ranges of 15 to 70 ng/dL (Bhasin et al., 2010, JCEM).
- Clinically diagnosed hypogonadism, defined as below 300 ng/dL with symptoms, affects an estimated 2 to 6 percent of adult men, not a majority.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Median testosterone in men aged 30 to 40 is approximately 600 ng/dL, not comparable to female reference ranges of 15 to 70 ng/dL (Bhasin et al., 2010, JCEM).
- Clinically diagnosed hypogonadism, defined as below 300 ng/dL with symptoms, affects an estimated 2 to 6 percent of adult men, not a majority.
- Anabolic steroids are FDA-approved for conditions including hypogonadism and HIV-related muscle wasting, making the therapeutic use argument legitimate (Bhasin et al., 1996, NEJM).
- TRT for confirmed hypogonadism targets restoration to normal physiological range (roughly 400 to 700 ng/dL) and is clinically distinct from supraphysiological performance dosing.
- Supraphysiological testosterone use carries documented risks including erythrocytosis, cardiovascular strain, and suppression of endogenous hormone production (Morgentaler et al., 2015, Mayo Clinic Proceedings).
- Prednisone is a glucocorticoid, not an anabolic steroid. Comparing the two to make a point about steroid safety is scientifically imprecise.
- Anyone experiencing symptoms of low testosterone should obtain a morning blood panel and consult an endocrinologist or urologist before considering any hormonal intervention.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Jubilee · TikTok creator
1.2M views on this video
Can #steroid users & #naturalbodybuilders find a #middleground? #fitness #bodybuilder #bodybuilding #workoutmotivation #jubilee #testosterone #trt #lowtestosterone #gymtok #debate
Sources & references
- [1]Bhasin et al., 2010
- [2]Khera et al., 2016
- [3]Bhasin et al., 1996
- [4]Kadi et al., 1999
- [5]Morgentaler et al., 2015
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Jubilee, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.